Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

Platinum/taxane combinations are widely used in patients with carcinoma of unknown primary (CUP), yielding response rates of 30% and median overall survival of 9–11 months in selected patients. Yet these combinations have not been subject to a randomised trial to overcome selection bias, a major pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Huebner, G, Link, H, Kohne, C H, Stahl, M, Kretzschmar, A, Steinbach, S, Folprecht, G, Bernhard, H, Al-Batran, S E, Schoffski, P, Burkart, C, Kullmann, F, Otremba, B, Menges, M, Hoffmann, M, Kaiser, U, Aldaoud, A, Jahn, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634671/
https://www.ncbi.nlm.nih.gov/pubmed/19066607
http://dx.doi.org/10.1038/sj.bjc.6604818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634671/
https://www.ncbi.nlm.nih.gov/pubmed/19066607
http://dx.doi.org/10.1038/sj.bjc.6604818

Ejemplares similares